https://www.selleckchem.com/pr....oducts/ldc195943-imt
No significant difference was observed between the 2 groups in oxygen saturation (primary end point). A significant difference was observed in favor of the midazolam group regarding the QoL assessed by VAS. Midazolam does not add to respiratory side effects when it is used with lidocaine for LAT, while patients' QoL is actually improved in this group. Therefore, in our department, we changed our startegy in favor of the association of lidocaine and midazolam. Midazolam does not add to respiratory side effects when it is used with
Mi piace
Commento
Condividi
